Fruquintinib, adebrelimab, and radiation for advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two drugs (fruquintinib and adebrelimab) plus low or high dose radiation for people with advanced colorectal cancer that has not responded to standard treatments. The goal is to see if this combination can shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your daily activities are not severely limited (ECOG score 0 or 1).
- Your colorectal cancer is MSS type (microsatellite stable).
- Your cancer has continued to grow after at least two standard treatments.
- You have at least one tumor that can be measured on scans.
- Your blood counts and organ function are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (cetuximab beta and fruquintinib) with or without an immunotherapy drug for people with a specific type of advanced colorectal cancer that has not been treated before. It aims to see if this approach is safe and effective for those whose tumors have certain genetic markers (RAS and BRAF wild type).
This trial tests a new combination of drugs (cadonilimab, fruquintinib) plus targeted radiation (SBRT) for people with advanced MSS colorectal cancer who have already tried several standard treatments. The goal is to see if this combination can help shrink tumors or slow disease progression.
This trial tests a new combination—an immunotherapy drug (cadonilimab) plus a targeted anti-angiogenesis pill (fruquintinib) and focused radiation (SBRT)—for people with MSS colorectal cancer that has progressed after at least two prior treatments. The goal is to see if this triple approach can help shrink or control the cancer better than standard options.
This trial tests a combination of three drugs (fruquintinib, chidamide, and sintilimab) for people with a specific type of metastatic colorectal cancer that has not responded to at least two prior treatments. It aims to see if this combination is safe and effective.
This study tests a combination of precisely targeted radiation (SBRT) with two drugs: fruquintinib (a pill that blocks blood supply to tumors) and antibodies that boost your immune system to fight cancer (PD-1 and CTLA-4 inhibitors). It is for people with advanced colorectal cancer who have already tried two standard chemotherapy treatments.
This trial tests a combination of two drugs (5-FU and fruquintinib) in people with advanced colorectal cancer that cannot be removed by surgery or has spread. It is for those who have not had chemotherapy before.
Hear when a new MSS Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.